NEW YORK, Oct 20 (Reuters) - Pfizer Inc. (PFE.N: Quote, Profile, Research) on Thursday said it will take one to three years to amass necessary clinical trial data for its cholesterol drug torcetrapib, the most important of its experimental drugs.
NEW YORK, Oct 20 (Reuters) - Pfizer Inc. (PFE.N: Quote, Profile, Research) on Thursday said it will take one to three years to amass necessary clinical trial data for its cholesterol drug torcetrapib, the most important of its experimental drugs.
